0001628280-22-018342.txt : 20220701
0001628280-22-018342.hdr.sgml : 20220701
20220701122115
ACCESSION NUMBER: 0001628280-22-018342
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220616
FILED AS OF DATE: 20220701
DATE AS OF CHANGE: 20220701
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Goldberg Andrew D.
CENTRAL INDEX KEY: 0001827722
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39614
FILM NUMBER: 221060414
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD, SUITE 160
CITY: IRVINE
STATE: CA
ZIP: 92618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001819790
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 814717861
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: (949) 409-9820
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
4
1
wf-form4_165669246081797.xml
FORM 4
X0306
4
2022-06-16
0
0001819790
Tarsus Pharmaceuticals, Inc.
TARS
0001827722
Goldberg Andrew D.
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE
CA
92618
1
0
0
0
Stock Option (right to buy)
12.89
2022-06-16
4
A
0
7000
0
A
2032-06-15
Common Stock
7000.0
7000
D
Restricted Stock Units
2022-06-16
4
A
0
2000
0
A
Common Stock
2000.0
2000
D
Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
/s/ Leonard M. Greenstein, Attorney-in-Fact
2022-07-01